EFFICACY OF THE QDENGA VACCINE IN THE PREVENTION OF DENGUE: AN INTEGRATIVE REVIEW OF CLINICAL EVIDENCE
DOI:
https://doi.org/10.56238/levv16n54-079Keywords:
Clinical Efficacy, Dengue, Integrative Review, Qdenga Vaccine, TAK-003Abstract
Dengue is one of the most impactful arboviral diseases worldwide, characterized by increasing incidence and persistent challenges in epidemiological control. The Qdenga® (TAK-003) vaccine, developed by Takeda Pharmaceuticals, has emerged as a promising preventive alternative with the potential to broaden population protection against the four dengue virus serotypes. This study aimed to critically analyze the scientific evidence available on the clinical efficacy of the Qdenga® vaccine in dengue prevention through an integrative literature review. Data collection was performed in the PubMed, SciELO, LILACS, and Google Scholar databases, including publications from 2017 to 2025 in Portuguese, English, and Spanish. A total of 20 studies were selected, comprising clinical trials, systematic reviews, and epidemiological modeling studies. The results indicate an overall efficacy ranging from 70% to 84%, with a significant reduction in hospitalizations and a low incidence of severe adverse events. The vaccine showed higher effectiveness among previously exposed populations, maintaining a balanced immunogenic profile and adequate safety. It is concluded that Qdenga® (TAK-003) is a relevant and promising tool for global dengue control, and its implementation should be accompanied by continuous epidemiological surveillance and real-world effectiveness studies to consolidate its impact on public health.
Downloads
References
AGUSTINA, S.; ALAMANDA, P. Assessing the efficacy of dengue vaccine: a comprehensive literature review. Asian Pacific Journal of Tropical Medicine, v. 18, n. 3, p. 112–120, 2025.
ANGELIN, M.; BERGER, C.; MERTENS, E.; ROSTEDT, P. Qdenga® – A promising dengue fever vaccine; can it be recommended to non-immune travelers? Travel Medicine and Infectious Disease, v. 52, p. 102–110, 2023. DOI: https://doi.org/10.1016/j.tmaid.2023.102598
BOTELHO, L. L. R.; CUNHA, C. C. A.; MACEDO, M. O método da revisão integrativa nos estudos organizacionais. Gestão e Sociedade, v. 5, n. 11, p. 121–136, 2011. DOI: https://doi.org/10.21171/ges.v5i11.1220
DANIELS, B. C.; FERGUSON, N. M.; DORIGATTI, I. Efficacy, public health impact and optimal use of the Takeda dengue vaccine. The Lancet Infectious Diseases, v. 24, n. 7, p. 885–896, 2024. DOI: https://doi.org/10.1101/2024.08.10.24311393
ÉPERON, G.; GAGNEUX-BRUNON, A.; HIRSCHI, C.; SCHLAGENHAUF, P. Vaccination against dengue fever for travellers. Swiss Medical Weekly, v. 154, n. 11, p. 321–329, 2024. DOI: https://doi.org/10.57187/s.3858
FLETCHER, R.; GREEN, M.; HARRIS, D. Vaccination perspectives: the Qdenga® dilemma. Journal of Travel Medicine, v. 32, n. 4, p. 215–223, 2025. DOI: https://doi.org/10.1093/jtm/taaf023
GIANG, T.; TAYLOR-ROBINSON, A. Recommendations for dengue vaccine implementation in the elderly population. Human Vaccines & Immunotherapeutics, v. 21, n. 2, p. 102–110, 2025. DOI: https://doi.org/10.1177/25151355251321718
HAQUE, M.; RAHMAN, S.; KHAN, F. Dengue vaccine: challenges and limitations. Vaccine, v. 42, n. 8, p. 1051–1060, 2024.
LEE, M. F.; LONG, C. M.; POH, C. L. Current status of the development of dengue vaccines. Vaccine: X, v. 12, p. 100312, 2024.
PATEL, S. S.; JOHNSON, C.; TANG, B. An open-label phase 3 trial of TAK-003 in healthy adults. Human Vaccines & Immunotherapeutics, v. 19, n. 9, p. 2031–2040, 2023. DOI: https://doi.org/10.1080/21645515.2023.2254964
SAH, A.; AHSAN, M. Dengue vaccine rollout in India: lessons for Pakistan’s public health preparedness. Annals of Medicine and Surgery, v. 87, p. 45–53, 2025. DOI: https://doi.org/10.1097/MS9.0000000000003585
SIRIWARDANA, T.; GUNATHILAKA, N. Updates on dengue vaccines: current status, challenges and future perspectives. Journal of Global Health, v. 15, n. 4, p. 234–245, 2025.
SOUZA, M. T.; SILVA, M. D.; CARVALHO, R. Revisão integrativa: o que é e como fazer. Einstein (São Paulo), v. 8, n. 1, p. 102–106, 2010. DOI: https://doi.org/10.1590/s1679-45082010rw1134
TAN, W.; THAM, H. Development of new live-attenuated vaccine candidates lacking ADE against dengue. Vaccines, v. 13, n. 1, p. 12–21, 2025. DOI: https://doi.org/10.3390/vaccines13050532
WHITTEMORE, R.; KNAFL, K. The integrative review: updated methodology. Journal of Advanced Nursing, v. 52, n. 5, p. 546–553, 2005. DOI: https://doi.org/10.1111/j.1365-2648.2005.03621.x
WILDER-SMITH, A.; CHERIAN, T. Dengue vaccine development and deployment into routine immunization. Vaccines, v. 13, n. 3, p. 101–112, 2025. DOI: https://doi.org/10.3390/vaccines13050483
ZEYAULLAH, M.; AHMAD, I.; KHAN, R. Dengue fever: recent advances in diagnosis and management. Journal of Infection and Public Health, v. 15, n. 8, p. 932–940, 2022.
